<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765752</url>
  </required_header>
  <id_info>
    <org_study_id>0707002830</org_study_id>
    <secondary_id>ESRC 057</secondary_id>
    <nct_id>NCT00765752</nct_id>
  </id_info>
  <brief_title>Cortical GABA Concentrations in Insomnia</brief_title>
  <official_title>The Association of Cortical GABA Concentrations in Subjects With Primary Insomnia and Depression in Partial Remission With Residual Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disturbances in the amino acid neurotransmitter (AANt), gamma-amino butyric acid (GABA)&#xD;
      function are hypothesized to contribute to the neurobiology of Major Depressive Disorder&#xD;
      (MDD) and insomnia. The principal objective of this project is to use magnetic resonance&#xD;
      spectroscopy (MRS) to provide the first in vivo characterization of cortical GABA levels in&#xD;
      individuals with primary insomnia, and to determine whether subjects with MDD, achieving a&#xD;
      partial response with selective serotonin reuptake inhibitor treatment but still experiencing&#xD;
      significant residual symptoms including insomnia, have altered levels of this&#xD;
      neurotransmitter. The investigators are also exploring the correlation between cortical AANt&#xD;
      levels and abnormalities in sleep parameters in primary insomnia and as a residual symptom of&#xD;
      major depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups of subjects (MDD with partial remission and residual insomnia, primary insomnia,&#xD;
      and healthy) will participate in the study. All subjects will complete a telephone screening,&#xD;
      and if appropriate a complete face-to-face evaluation, to determine their eligibility for the&#xD;
      study. All subjects meeting eligibility criteria for the study will complete a baseline MRS&#xD;
      session to evaluate differences in GABA concentrations between the three groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cortical GABA levels as measured by proton MRS</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory polysomnography</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Insomnia</condition>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>1 Primary Insomnia</arm_group_label>
    <description>Individuals with insomnia not related to another identified cause.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Healthy comparison subjects</arm_group_label>
    <description>Healthy subjects with no history of insomnia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient Sample.&#xD;
&#xD;
          -  Healthy subjects without insomnia (Group A) (n=10)&#xD;
&#xD;
          -  Subjects with primary insomnia (Group B) (n=20)&#xD;
&#xD;
          -  Subjects with a history of major depressive disorder and currently in partial&#xD;
             remission but with residual insomnia (Group C) (n=20)&#xD;
&#xD;
        Inclusion Criteria for Primary Insomnia Subjects:&#xD;
&#xD;
          -  Males or females between the ages of 25 and 55 years&#xD;
&#xD;
          -  Clinical diagnosis of primary insomnia meeting DSM-IV criteria.&#xD;
&#xD;
          -  Current insomnia ratings (current Sleep Onset Latency SOL &gt; 30 minutes, Insomnia&#xD;
             Severity Index (ISI) &gt; 14, total sleep time (TST) &lt; 6.5 hrs/night).&#xD;
&#xD;
          -  No lifetime history of psychopathology other than primary insomnia.&#xD;
&#xD;
          -  No sleep disorders previously identified as related to other conditions including&#xD;
             sleep disordered breathing, restless leg syndrome, periodic limb movement disorder,&#xD;
             chronic pain, gastro-esophageal reflux disease, sleep paralysis, nocturnal seizures,&#xD;
             nocturia, enuresis; also narcolepsy and REM behavior disorders (assessed by clinical&#xD;
             interview and Harvard Center and Cognition Habitual Sleep Survey).&#xD;
&#xD;
        Inclusion Criteria for Depressed Subjects:&#xD;
&#xD;
          -  Males or females between the ages of 25 and 55 years&#xD;
&#xD;
          -  Clinical diagnosis of major depression meeting DSM-IV criteria in partial remission&#xD;
             (HDRS-8-17), confirmed after semi-structured interview with the SCID and HDRS.&#xD;
&#xD;
          -  On monotherapy with a single SSRI medication for a period of at least 6-weeks.&#xD;
&#xD;
          -  Remaining symptoms of insomnia (current Sleep Onset Latency (SOL) &gt; 30 minutes,&#xD;
             Insomnia Severity Index (ISI) &gt; 14, TST &lt; 6.5 hrs/night).&#xD;
&#xD;
          -  Participation is judged clinically appropriate by treatment team.&#xD;
&#xD;
          -  No sleep disorders previously identified as related to other conditions including&#xD;
             sleep disordered breathing, restless leg syndrome, periodic limb movement disorder,&#xD;
             chronic pain, gastro-esophageal reflux disease, sleep paralysis, nocturnal seizures,&#xD;
             nocturia, enuresis; also narcolepsy and REM behavior disorders.&#xD;
&#xD;
        Inclusion Criteria for Healthy Control Subjects:&#xD;
&#xD;
          -  Males or females between the ages of 25 and 55 years&#xD;
&#xD;
          -  No lifetime history of psychopathology or insomnia (current SOL &lt; 30mins, ISI &lt; 4, TST&#xD;
             &gt; 6.5 hrs)&#xD;
&#xD;
          -  At low risk for depression (e.g., no first degree relative with child onset,&#xD;
             recurrent, psychotic or bipolar depression)&#xD;
&#xD;
        Exclusion Criteria for all Subjects:&#xD;
&#xD;
          -  History of serious medical or neurological illness&#xD;
&#xD;
          -  Signs of major medical or neurological illness on examination or as a result of&#xD;
             laboratory studies&#xD;
&#xD;
          -  History of psychoactive substance and/or alcohol dependence or abuse in past 6-months.&#xD;
&#xD;
          -  Current use of any psychoactive medication or substance (with the exception of&#xD;
             caffeine, as noted below, and the use of an SSRI in the depressed group), during the&#xD;
             two weeks prior to the initial scan.&#xD;
&#xD;
          -  More than the caffeine-equivalent of 3 cups of coffee per day, or any regular (i.e.,&#xD;
             more than 1x/2 weeks) use of caffeine after 7pm.&#xD;
&#xD;
          -  Use of benzodiazepines or olanzapine in past 3-months.&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Any implanted metal devise or metal fragments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Sanacora, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Depression Research Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Gerard Sanacora</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>depression</keyword>
  <keyword>GABA</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>MRS</keyword>
  <keyword>Sleep</keyword>
  <keyword>antidepressant medication use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

